niacinamide has been researched along with Facial Dermatoses in 12 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Facial Dermatoses: Skin diseases involving the FACE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In both studies, the combination formulation was significantly more effective than the vehicle and the 5% niacinamide formulation in reducing the appearance of hyperpigmentation after 8 weeks." | 9.14 | Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide. ( Bissett, DL; Hakozaki, T; Kelm, GR; Li, J; Miyamoto, K; Raleigh, PS; Robinson, LR, 2009) |
| "A multicenter prospective observational study was carried out on patients with a diagnosis of mild comedonal-papular facial acne to provide new evidence on the clinical effectiveness, tolerability and acceptability of three salicylic acid-based products for the topical treatment of acne in the daily clinical practice." | 7.96 | Effectiveness of a combination of salicylic acid-based products for the treatment of mild comedonal-papular acne: a multicenter prospective observational study. ( Bettoli, V; Micali, G; Monfrecola, G; Veraldi, S, 2020) |
| "In both studies, the combination formulation was significantly more effective than the vehicle and the 5% niacinamide formulation in reducing the appearance of hyperpigmentation after 8 weeks." | 5.14 | Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide. ( Bissett, DL; Hakozaki, T; Kelm, GR; Li, J; Miyamoto, K; Raleigh, PS; Robinson, LR, 2009) |
| "To investigate the effects of niacinamide on melanogenesis in vitro and on facial hyperpigmentation and skin colour in vivo in Japanese women." | 5.10 | The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. ( Bissett, DL; Boissy, RE; Chhoa, M; Greatens, A; Hakozaki, T; Hillebrand, GG; Matsubara, A; Minwalla, L; Miyamoto, K; Zhuang, J, 2002) |
| "A multicenter prospective observational study was carried out on patients with a diagnosis of mild comedonal-papular facial acne to provide new evidence on the clinical effectiveness, tolerability and acceptability of three salicylic acid-based products for the topical treatment of acne in the daily clinical practice." | 3.96 | Effectiveness of a combination of salicylic acid-based products for the treatment of mild comedonal-papular acne: a multicenter prospective observational study. ( Bettoli, V; Micali, G; Monfrecola, G; Veraldi, S, 2020) |
| "Rosacea is a chronic facial dermatosis with a progressive course, which is characterized by the presence of erythema, papules, pustules, telangiectasias and sebaceous gland hyperplasia." | 1.33 | Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. ( Gebicki, J; Sysa-Jedrzejowska, A; Wieczorkowska, M; Wozniacka, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bettoli, V | 1 |
| Micali, G | 1 |
| Monfrecola, G | 1 |
| Veraldi, S | 1 |
| Desai, S | 1 |
| Ayres, E | 1 |
| Bak, H | 1 |
| Manco, M | 1 |
| Lynch, S | 1 |
| Raab, S | 1 |
| Du, A | 1 |
| Green, D | 1 |
| Skobowiat, C | 1 |
| Wangari-Talbot, J | 1 |
| Zheng, Q | 1 |
| Lee, DH | 1 |
| Oh, IY | 1 |
| Koo, KT | 1 |
| Suk, JM | 1 |
| Jung, SW | 1 |
| Park, JO | 1 |
| Kim, BJ | 1 |
| Choi, YM | 1 |
| Bissett, DL | 3 |
| Robinson, LR | 2 |
| Raleigh, PS | 2 |
| Miyamoto, K | 3 |
| Hakozaki, T | 3 |
| Li, J | 2 |
| Kelm, GR | 2 |
| Weisshaupt, Ch | 1 |
| Budak, K | 1 |
| Pestalozzi, B | 1 |
| Bissett, D | 1 |
| Chen, S | 1 |
| Lu, X | 1 |
| Zhou, G | 1 |
| Wozniacka, A | 1 |
| Wieczorkowska, M | 1 |
| Gebicki, J | 1 |
| Sysa-Jedrzejowska, A | 1 |
| Draelos, ZD | 1 |
| Ertel, K | 1 |
| Berge, C | 1 |
| Kong, HH | 1 |
| Cowen, EW | 1 |
| Azad, NS | 1 |
| Dahut, W | 1 |
| Gutierrez, M | 1 |
| Turner, ML | 1 |
| Minwalla, L | 1 |
| Zhuang, J | 1 |
| Chhoa, M | 1 |
| Matsubara, A | 1 |
| Greatens, A | 1 |
| Hillebrand, GG | 1 |
| Boissy, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
2 reviews available for niacinamide and Facial Dermatoses
| Article | Year |
|---|---|
Topical niacinamide and barrier enhancement.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Epidermis; Facial Dermatoses; Humans; Keratolyt | 2002 |
Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine.
Topics: Acetylglucosamine; Administration, Topical; Adult; Aged; Asian People; Dose-Response Relationship, D | 2007 |
5 trials available for niacinamide and Facial Dermatoses
| Article | Year |
|---|---|
Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Facial Dermatoses; Female; Humans; Hyperpigme | 2019 |
Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Delayed-Action Preparations; Dermatologic A | 2014 |
Reduction in the appearance of facial hyperpigmentation by topical N-undecyl-10-enoyl-L-phenylalanine and its combination with niacinamide.
Topics: Administration, Topical; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Facial Dermato | 2009 |
Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea.
Topics: Administration, Topical; Emollients; Epidermis; Facial Dermatoses; Female; Galvanic Skin Response; H | 2005 |
The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
Topics: Adolescent; Adult; Cell Culture Techniques; Coculture Techniques; Dose-Response Relationship, Drug; | 2002 |
5 other studies available for niacinamide and Facial Dermatoses
| Article | Year |
|---|---|
Effectiveness of a combination of salicylic acid-based products for the treatment of mild comedonal-papular acne: a multicenter prospective observational study.
Topics: Acne Vulgaris; Adult; Carbamide Peroxide; Dermatologic Agents; Drug Combinations; Facial Dermatoses; | 2020 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Drug Therapy, Combination; Facial Dermatoses; Humans | 2003 |
Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study.
Topics: Administration, Topical; Adult; Chronic Disease; Dermatologic Agents; Facial Dermatoses; Female; Gel | 2005 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanth | 2007 |